Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
STRN-ALK rearrangement
i
Other names:
NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor, STRN, Striatin, Protein Phosphatase 2 Regulatory Subunit B'''Alpha, Striatin Calmodulin Binding Protein, Striatin Calmodulin-Binding Protein, PPP2R6A, SG2NA, STRN1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
238
;
6801
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
ALK positive (74)
ALK negative (4)
EGFR negative + ALK negative (4)
EGFR expression + ALK positive (3)
ALK expression + PDGFRA expression (1)
ALK expression + PDGFRB expression (1)
ALK overexpression (1)
ALK positive + ROS1 positive (1)
ALK positive + YAP1 overexpression (1)
ALK positive + YES1 overexpression (1)
KRT7 positive + NKX2-1 positive + ALK overexpression (1)
ALK positive (74)
ALK negative (4)
EGFR negative + ALK negative (4)
EGFR expression + ALK positive (3)
ALK expression + PDGFRA expression (1)
ALK expression + PDGFRB expression (1)
ALK overexpression (1)
ALK positive + ROS1 positive (1)
ALK positive + YAP1 overexpression (1)
ALK positive + YES1 overexpression (1)
KRT7 positive + NKX2-1 positive + ALK overexpression (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
STRN-ALK rearrangement
Mesothelioma
STRN-ALK rearrangement
Mesothelioma
crizotinib
Sensitive: C4 – Case Studies
crizotinib
Sensitive
:
C4
crizotinib
Sensitive: C4 – Case Studies
crizotinib
Sensitive
:
C4
STRN-ALK rearrangement
Mesothelioma
STRN-ALK rearrangement
Mesothelioma
ABT 263
Sensitive: D – Preclinical
ABT 263
Sensitive
:
D
ABT 263
Sensitive: D – Preclinical
ABT 263
Sensitive
:
D
STRN-ALK rearrangement
Mesothelioma
STRN-ALK rearrangement
Mesothelioma
cobimetinib
Sensitive: D – Preclinical
cobimetinib
Sensitive
:
D
cobimetinib
Sensitive: D – Preclinical
cobimetinib
Sensitive
:
D
STRN-ALK rearrangement
Mesothelioma
STRN-ALK rearrangement
Mesothelioma
ceritinib + PF-05212384
Sensitive: D – Preclinical
ceritinib + PF-05212384
Sensitive
:
D
ceritinib + PF-05212384
Sensitive: D – Preclinical
ceritinib + PF-05212384
Sensitive
:
D
STRN-ALK rearrangement
Mesothelioma
STRN-ALK rearrangement
Mesothelioma
ensartinib
Sensitive: D – Preclinical
ensartinib
Sensitive
:
D
ensartinib
Sensitive: D – Preclinical
ensartinib
Sensitive
:
D
STRN-ALK rearrangement
Mesothelioma
STRN-ALK rearrangement
Mesothelioma
trametinib
Sensitive: D – Preclinical
trametinib
Sensitive
:
D
trametinib
Sensitive: D – Preclinical
trametinib
Sensitive
:
D
STRN-ALK rearrangement
Mesothelioma
STRN-ALK rearrangement
Mesothelioma
cobimetinib + ceritinib
Sensitive: D – Preclinical
cobimetinib + ceritinib
Sensitive
:
D
cobimetinib + ceritinib
Sensitive: D – Preclinical
cobimetinib + ceritinib
Sensitive
:
D
STRN-ALK rearrangement
Mesothelioma
STRN-ALK rearrangement
Mesothelioma
ceritinib
Sensitive: D – Preclinical
ceritinib
Sensitive
:
D
ceritinib
Sensitive: D – Preclinical
ceritinib
Sensitive
:
D
STRN-ALK rearrangement
Mesothelioma
STRN-ALK rearrangement
Mesothelioma
brigatinib
Sensitive: D – Preclinical
brigatinib
Sensitive
:
D
brigatinib
Sensitive: D – Preclinical
brigatinib
Sensitive
:
D
STRN-ALK rearrangement
Mesothelioma
STRN-ALK rearrangement
Mesothelioma
cisplatin + gemcitabine
Resistant: D – Preclinical
cisplatin + gemcitabine
Resistant
:
D
cisplatin + gemcitabine
Resistant: D – Preclinical
cisplatin + gemcitabine
Resistant
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.